Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Mallard/Netherlands/00/95 (H7N3) Influenza Vaccine

NCT01511419 is registered in ClinicalTrials.gov with PATH as lead sponsor.

NCT NCT01511419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01511419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Mallard/Netherlands/00/95 (H7N3) Influenza Vaccine
Lead sponsor
PATH
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2012
Completion date
July 31, 2012
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

avian influenza, influenza